OnKure Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Boulder, CO
OKUR chart
What traders are saying about $OKUR
Latest postsOnKure Therapeutics, Inc. news
- OnKure Therapeutics, Inc. Estimates – NASDAQ:OKUR
TradingView ·
- Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape
StreetInsider ·
- OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Yahoo Finance ·
- OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Yahoo Finance ·
- OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
marketbeat.com ·
- OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
Yahoo Finance ·
- OnKure Therapeutics Reports First Quarter 2026 Financial Results
Yahoo Finance ·
- TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Yahoo Finance ·
- OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
Yahoo Finance ·
- OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Yahoo Finance ·
- Promising Penny Stocks To Watch In December 2025
Yahoo Finance ·
- 3 Promising Penny Stocks With Market Caps Under $200M
Yahoo Finance ·
OnKure Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $0 | – | – |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M |
| Diluted EPS | $-4.40 | $-15.28 | $-124.41 | $-2.12 |
| Total assets (year end) | $62.1M | $114.9M | $35.7M | $108.2M |
| Cash and equivalents (year end) | $59.0M | $110.8M | $29.9M | $19.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About OnKure Therapeutics, Inc.
- Ticker
- OKUR (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boulder, CO
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1637715
- Former names
- Reneo Pharmaceuticals, Inc.
Frequently asked questions
What exchange is OnKure Therapeutics, Inc. listed on?
OnKure Therapeutics, Inc. trades on the Nasdaq under the ticker symbol OKUR.
What industry is OnKure Therapeutics, Inc. in?
OnKure Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is OnKure Therapeutics, Inc. headquartered?
OnKure Therapeutics, Inc.'s business address on file with the SEC is in Boulder, CO.
When does OnKure Therapeutics, Inc.'s fiscal year end?
OnKure Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did OnKure Therapeutics, Inc. report?
OnKure Therapeutics, Inc. reported $0 in revenue for calendar year 2024, according to its SEC filings.